E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Eli Lilly, Bayer, AstraZeneca, Bristol Myers Squibb, Clovis, Merck, Curium, Blue Earth Diagnostics, Foundation Medicine, Exact Sciences and Invitae; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Bristol Myers Squibb, Bayer, AstraZeneca, Clovis and Merck; and is the co-inventor of a patented AR-V7 biomarker technology that has been licensed to Qiagen. J.J.O. receives research support from the National Cancer Institute (K12 CA90628-23) and the Prostate Cancer Foundation and previously received support from Genentech, Partner Therapeutics and NaNotics. S.M.D. has served as a paid consultant/advisor to Janssen, Bristol Myers Squibb and Oncternal Therapeutics and as principal investigator on grants awarded to the University of Minnesota by Janssen and Pfizer/Astellas.